Clinical trials: Bile Duct Neoplasm
Congenital Biliary Dilatation
Congenital Biliary Dilatation Diagnosis Based on 3D Morphological Characteristics
Congenital biliary dilatation necessitates timely intervention owing to potential complications. This study endeavors to enhance diagnostic precision using quantitative three-dimensional morphological characteristics.
- Trial name
- NCT06162520
- Testing
- Contrast-enhanced computed tomography (CECT) and 3D morphological analysis
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Tsinghua University
Hepatocellular Carcinoma, Bile Duct Cancer
FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy
The purpose of this study is to explore the ability of positron emission tomography (PET) with [68Ga]FAPI to detect, evaluate treatment response, and predict prognosis in advanced liver and biliary cancer patients treated with…
- Trial name
- NCT05662488
- Testing
- [68Ga]FAPI PET/CT and [18F]FDG PET/CT
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Cholangiocarcinoma, Klatskin Tumor
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting.
- Conditions
- Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
- Trial name
- ACTICCA-2 (NCT06175845)
- Testing
- Intraductal biliary radiofrequency ablation
- Where
- 9 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
Drugs used in chemotherapy work different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00047307
- Testing
- alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03684811
- Testing
- FT-2102, Azacitidine, Nivolumab
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 93 people
- Sponsor
- Forma Therapeutics, Inc.
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary Pancreatic Cancer With Severe Obstructive Jaundice
This trial studies the side effects of self expanding metal stent (SEMS) placement before surgery in unblocking the bile duct in patients with periampullary pancreatic cancer with severe obstructive jaundice.
- Trial name
- NCT03820544
- Testing
- Endoscopic Retrograde Cholangiopancreatography, Standard of care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Gallbladder Carcinoma, Metastatic Cholangiocarcinoma
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
This randomized phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body (metastatic) and cannot be removed by surgery…
- Conditions
- Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03201458
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 41 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Carcinomas/Neoplasms
Evolution® Biliary Stent System-Fully Covered
The Evolution® Biliary Stent System-Fully Covered study is a clinical trial approved by the US FDA to evaluate the effectiveness of the Evolution® Biliary Stent System-Fully Covered when used in palliation of malignant neoplasms…
- Trial name
- NCT02104076
- Testing
- Evolution® Biliary Stent-Fully Covered
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 90 people
- Sponsor
- Cook Group Incorporated
Biliary Disease, Pancreatitis
Los Angeles Prospective GI Biliary and EUS Series
Endoscopic retrograde cholangiopancreatography and endoscopic ultrasound are increasingly being used to manage complex disease of the bile duct, pancreas and cancer.
- Conditions
- Biliary Disease, Pancreatitis, Gastrointestinal Neoplasms
- Trial name
- NCT02196935
- Testing
- clinical course
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- University of Southern California
Choledocholithiasis, Choledocholithiasis With Acute Cholangitis
Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography
Endoscopic retrograde cholangiopancreatography (ERCP) is a technique which combines endoscopic and radiological vision and allows for therapeutic procedures on pathologies of the pancreas and bile duct.
- Conditions
- Choledocholithiasis, Choledocholithiasis With Acute Cholangitis, Cholangiocarcinoma, Sclerosing Cholangitis
- Trial name
- NCT06670547
- Testing
- Endoscopic retrograde cholangiopancreatography (ERCP)
- Volunteers
- 3,000 people
- Sponsor
- Germans Trias i Pujol Hospital
Pancreatic Adenocarcinoma, Cholangiocarcinoma
The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract
The aim of the present study is to research histological and molecular markers in patients with neoplasia of the gastrointestinal tract.
- Conditions
- Pancreatic Adenocarcinoma, Cholangiocarcinoma, Colon Cancer
- Trial name
- SOCRATE (NCT06728358)
- Testing
- Molecular analyses
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Cancer, Cholangiocarcinoma
[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer
The goal of this clinical trial is to evaluate the clinical use of [68Ga]Ga-FAPI-46 PET (positron emission tomography)/CT (computed tomography) imaging in patients with pancreatic or bile duct cancer.
- Trial name
- PANSCAN-1 (NCT05957250)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Netherlands
- Volunteers
- 63 people
- Sponsor
- Amsterdam UMC, location VUmc
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Liver and Intrahepatic Bile Duct Carcinoma
CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization
This trial studies the use of computed tomography (CT) perfusion scans in detecting changes in blood flow to the liver after portal vein embolization in patients with liver cancer.
- Trial name
- NCT03990623
- Testing
- Computed Tomography Perfusion Imaging, Liver Biopsy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and…
- Trial name
- NCT00919061
- Testing
- Gemcitabine, Cisplatin, Sorafenib
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Congenital Hydronephrosis, Congenital Choledochal Cyst
Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children
Etomidate is an unique drug used for induction of general anesthesia and sedation. Adrenal cortical inhibition by etomidate has received much attention.
- Conditions
- Congenital Hydronephrosis, Congenital Choledochal Cyst, Fracture
- Trial name
- NCT02013986
- Testing
- etomidate, midazolam, propofol
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Du yi
BCL2 Gene mRNA Overexpression
Validation of Useful Markers Generated by Next Generation Bio-data Based Genome Research and Cohort Study
Multiple biomarker development through validation of useful markers generated by next generation bio-data based genome research and cohort study
- Trial name
- miRNA_Chip (NCT02807896)
- Where
- South Korea
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- CHANGHEE LEE
Choledocholithiasis, Cholangiocarcinoma
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
When a doctor performs Endoscopic retrograde cholangiopancreatography "ERCP" (Endoscopy to examine the bile duct) a flexible tube is inserted into the mouth and into the stomach.
- Conditions
- Choledocholithiasis, Cholangiocarcinoma, Benign Stricture of Common Bile Duct
- Trial name
- NCT01673269
- Testing
- Blood culture ( aerobic and anaerobic)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso